Can Ketamine For Depression Be Improved? New Study Will Looks Into Ketamine Analog Arketamine

Perception Neuroscience, an Atai Life Sciences (NASDAQ: ATAI) subsidiary, is starting a Phase 2a clinical trial on PCN-101, its lead drug candidate.

The study will evaluate the safety and efficacy of a proprietary formulation of arketamine that could have a similar therapeutic action to ketamine in the treatment of depression, with less dissociative effects.

The Phase 2a trial is a double blind, placebo-controlled study in with treatment-resistant depression. Three parallel arms will enroll 31 at …

Full story available on Benzinga.com

More Can Ketamine For Depression Be Improved? New Study Will Looks Into Ketamine Analog Arketamine